NCT00307398 - Anecortave Acetate Risk-Reduction Trial (AART) | Biotech Hunter

Enrollment

2,596

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Dry AMD

Interventions

DRUG

Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg

One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.

OTHER

Anecortave Acetate Vehicle

One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.

Trial Locations (1)

76134

Study Centers in the United States and Globally, Fort Worth